APPLICATIONS PUBLISHED 2 APRIL 2003

Published: 1-Oct-2003

The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492


The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. T +43 1521 260 F +43 1 52126 4492

  • Praziquantel compsns for treating diseases due to sarcocystis, neospora, toxoplasma and isospora
    Bayer 1296686*

  • Treatment of male sexual dysfunction
    Pfizer 1296687*

  • Bactericidal antimicrobial methods and compsns for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide, oxy amide or 8-hydroxy quinoline structure
    Influx 1296688*

  • Method of administering biphosphonates
    Novartis 1296689*

  • Method for treatment or prevention of flavivirus infections using nucleoside analogues
    Shire Bio-Chem 1296690*

  • Cellulose sulphate and other sulphated polysaccharides to prevent and treat papilloma virus infections and other infections
    Polydex Pharmaceuticals; Rush-Presbyterian-St. Luke's Medical Centre 1296691*

  • Use of a formulation made of or containing at least one dissimulated milk serum
    Sericausa 1296692*

  • Immunotherapy or treating bacterial or viral infection at mucosal surfaces with probiotics, and compsns therefore
    Mucoprotec 12296693*

  • Probiotics in primary prevention of atopic diseases
    OY Aboatech 1296694*

  • Use of a polysaccharide excreted by the Vibrio diabolicus species in bone repair
    IFREMER (Institut Francais de Recherche pour l'Exploitation de la Mer) 1296695*

  • Herbal compsn for the treatment and curing of diseases
    Skopichenko Dettwiler 1296696*

  • Therapeutic agents - I
    Peplin Research 1296697*

  • Therapeutic agents - II
    Peplin Research 1296698*

  • Therapeutic agents - III
    Peplin Research 1296699*

  • Anti-carcinogenic activity of hydroxylated chalcone compounds extracted from licorice root
    Rutgers, The State University; University of Medicine and Dentistry of New Jersey 1296700*

  • Use of Grifola frondosa fungus extracts
    Cognis France 1296701*

  • Neuroprotective peptides
    Ortho-McNeil Pharmaceutical 1296702*

  • Non-antibacterial tetracycline as anti-fungal agents
    Liu, Yu 1296703*

  • Peptides with physiological activity
    Zaveri, Chanda Bhuwalka 1296704*

  • Neurotoxic oligomers
    Prana Biotechnology; The General Hospital Corp 1296705*

  • Osetoclast secreted chemokine and uses thereof
    The UAB Research Foundation 1296706*

  • Methods of treating viral diseases with IL-18 and IL-18 combinations
    SmithKline Beecham 1296707*

  • Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD)
    Pharmagene Laboratories 1296708*

  • Solubilised protein vaccines
    Ferring 1296709*

  • Recombinant vaccines against infectious bursal disease virus
    Rahan Meristem 1296710*

  • You may also like